DeepNewz Markets

Markets Stories

Search

Loading...

Browse all stories on DeepNewz

Rite Aid Wins $200 Million Dispute Over Elixir Sale After Judge's Monday Ruling

Jun 24, 2024, 06:00 PM

Rite Aid has successfully defeated MedImpact Healthcare Systems in a $200 million dispute over the sale of its pharmacy benefit manager, Elixir. A judge ruled on Monday that MedImpact is not entitled to recoup the $200 million in extra costs, as it assumed Elixir's debts when it acquired the company. This ruling absolves Rite Aid of any responsibility for the additional costs tied to the recent acquisition.

View original story

Markets

Loading...

Looking for markets...

MedImpact appeals the court ruling by September 30, 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

No • 50%

Yes • 50%

Public court records or official press releases from MedImpact

MedImpact to appeal Elixir sale ruling by end of 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

No • 50%

Yes • 50%

Official court records and public announcements

MedImpact to file new lawsuit against Rite Aid in 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

No • 50%

Yes • 50%

Court records and public legal filings

Rite Aid faces further legal challenges by end of 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Yes • 50%

No • 50%

Public court records or official press releases from the involved parties

Rite Aid stock price up by 10% by July 31, 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

No • 50%

Yes • 50%

Stock market data from financial news platforms like Bloomberg or Reuters

Rite Aid stock to rise by more than 10% by end of July 2024?

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Yes • 50%

No • 50%

Stock market data from financial information services such as Yahoo Finance or Bloomberg

Change in Rite Aid's market cap by end of 2024

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Increase by more than 20% • 25%

Decrease by more than 20% • 25%

Decrease by 0-20% • 25%

Increase by 0-20% • 25%

Market capitalization data from financial information services such as Yahoo Finance or Bloomberg

Future acquisition offers for Elixir by end of 2024

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Yes, from a major healthcare company • 50%

No acquisition offers • 25%

Yes, from a financial or investment firm • 25%

Official press releases from Rite Aid or the acquiring company

Next acquirer of Elixir after the ruling

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

CVS Health • 25%

Cigna • 25%

No acquisition • 25%

Walgreens Boots Alliance • 25%

Official acquisition announcements and news reports

Percentage change in Rite Aid's stock price one month after ruling

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Increase by more than 10% • 25%

Decrease by more than 10% • 25%

Decrease by 0-10% • 25%

Increase by 0-10% • 25%

Stock market data from financial information services such as Yahoo Finance or Bloomberg

Rite Aid financial performance Q3 2024

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Meets Expectations • 33%

Above Expectations • 33%

Below Expectations • 33%

Quarterly financial reports released by Rite Aid

Rite Aid's market position by end of 2024

Rite Aid•MedImpact Healthcare Systems•Elixir•MedImpact

Resolution / Starting Odds

Top 4-6 • 33%

Top 3 • 33%

Below Top 6 • 33%

Market share data from industry analysis reports